Display options
Cite
Meintjes G, Dunn L, Coetsee M, et al. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. 2015;12:39doi: 10.1186/s12981-015-0081-8.
Meintjes, G., Dunn, L., Coetsee, M., Hislop, M., Leisegang, R., Regensberg, L., & Maartens, G. (2015). Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS research and therapy, 1239. https://doi.org/10.1186/s12981-015-0081-8
Meintjes, Graeme, et al. "Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study." AIDS research and therapy vol. 12 (2015): 39. doi: https://doi.org/10.1186/s12981-015-0081-8
Meintjes G, Dunn L, Coetsee M, Hislop M, Leisegang R, Regensberg L, Maartens G. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. 2015 Dec 01;12:39. doi: 10.1186/s12981-015-0081-8. eCollection 2015. PMID: 26628902; PMCID: PMC4666151.
Copy Download .nbib Format: NLM
Share it on

AIDS Res Ther. 2015 Dec 01;12:39. doi: 10.1186/s12981-015-0081-8. eCollection 2015.

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study.

AIDS research and therapy

Graeme Meintjes, Liezl Dunn, Marla Coetsee, Michael Hislop, Rory Leisegang, Leon Regensberg, Gary Maartens

Affiliations

  1. Clinical Infectious Diseases Research Initiative (CIDRI), Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925 South Africa ; Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa ; Department of Medicine, Imperial College London, London, UK.
  2. Aid for AIDS Management, Afrocentric Health Pty Ltd, The Boulevard, Block G, Searle Street, Woodstock, 7925 South Africa.
  3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Groote Schuur Hospital Old Main Building, Observatory, Cape Town, 7925 South Africa.

PMID: 26628902 PMCID: PMC4666151 DOI: 10.1186/s12981-015-0081-8

Abstract

BACKGROUND: An increasing number of patients in Africa are experiencing virologic failure on second-line antiretroviral therapy (ART) and those who develop resistance to protease inhibitors (PI) will require third-line ART, but no data on the outcomes of third-line are available from the region. We assessed the virologic outcomes and survival of patients started on salvage ART in a Southern African private sector disease management programme.

METHODS: Retrospective observational cohort study with linkage to the national death register. Adults (≥18 years) who started salvage ART between July 2007 and December 2011 were included. Salvage ART was defined by inclusion of darunavir or tipranavir in an ART regimen after having failed another PI. For Kaplan-Meier (KM) analysis, patients were followed up until event, or censored at death (only for virologic outcomes), leaving the programme, or April 2014.

RESULTS: 152 patients were included. Subtype was known for 113 patients: 111 (98 %) were infected with subtype C. All 152 had a genotype resistance test demonstrating major PI resistance mutations. Salvage drugs included were: darunavir/ritonavir (n = 149), tipranavir/ritonavir (n = 3), raltegravir (n = 58), and etravirine (n = 8). Median follow-up was 2.5 years (IQR = 1.5-3.3). 82.9 % achieved a viral load ≤400 copies/ml and 71.1 % ≤50 copies/ml. By the end of the study 17 (11.2 %) of the patients had died. The KM estimate of cumulative survival was 87.2 % at 2000 days.

CONCLUSIONS: Virologic suppression was comparable to that demonstrated in clinical trials and observational studies of salvage ART drugs conducted in other regions. Few deaths occurred during short term follow-up. Third-line regimens for patients with multidrug resistant subtype C HIV in Africa are virologically and clinically effective.

Keywords: Antiretroviral therapy; HIV; Human immunodeficiency virus; Salvage; Third-line; Virologic failure

References

  1. AIDS. 2010 Feb 20;24(4):563-72 - PubMed
  2. Antivir Ther. 2010;15(8):1161-9 - PubMed
  3. AIDS Res Treat. 2011;2011:769627 - PubMed
  4. AIDS. 2011 Jul 17;25(11):1365-9 - PubMed
  5. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93 - PubMed
  6. PLoS Med. 2009 Dec;6(12):e1000189 - PubMed
  7. Antivir Ther. 2009;14(6):859-64 - PubMed
  8. Braz J Infect Dis. 2013 Jan-Feb;17(1):41-7 - PubMed
  9. Mol Biol Int. 2012;2012:256982 - PubMed
  10. AIDS. 2010 Sep 10;24(14):2171-9 - PubMed
  11. AIDS. 2014 Jun 1;28(9):1373-4 - PubMed
  12. PLoS One. 2013 Dec 23;8(12):e82724 - PubMed
  13. N Engl J Med. 2011 Aug 18;365(7):637-46 - PubMed
  14. AIDS. 2008 Mar 12;22(5):611-6 - PubMed
  15. AIDS. 2012 Aug 24;26(13):1679-84 - PubMed
  16. J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):63-8 - PubMed
  17. J Antimicrob Chemother. 2013 Sep;68(9):1994-2002 - PubMed
  18. PLoS One. 2013 Sep 17;8(9):e73582 - PubMed
  19. Clin Infect Dis. 2010 Feb 15;50(4):605-12 - PubMed
  20. AIDS Res Ther. 2015 Sep 24;12:31 - PubMed
  21. PLoS One. 2013 Jun 26;8(6):e67188 - PubMed
  22. J Clin Virol. 2010 Mar;47(3):248-52 - PubMed
  23. Clin Infect Dis. 2009 Nov 1;49(9):1441-9 - PubMed

Publication Types

Grant support